Brooktree Capital Management lifted its position in Pfizer Inc. (NYSE:PFE) by 4.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 93,750 shares of the biopharmaceutical company’s stock after purchasing an additional 4,164 shares during the period. Pfizer comprises approximately 2.9% of Brooktree Capital Management’s portfolio, making the stock its 11th biggest holding. Brooktree Capital Management’s holdings in Pfizer were worth $3,440,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Nordea Investment Management AB lifted its position in shares of Pfizer by 65.3% during the 2nd quarter. Nordea Investment Management AB now owns 22,272,402 shares of the biopharmaceutical company’s stock valued at $719,176,000 after acquiring an additional 8,798,233 shares during the last quarter. Two Sigma Advisers LP raised its holdings in Pfizer by 74.8% during the 2nd quarter. Two Sigma Advisers LP now owns 11,066,501 shares of the biopharmaceutical company’s stock worth $361,875,000 after purchasing an additional 4,736,500 shares during the last quarter. BlackRock Inc. raised its stake in Pfizer by 0.8% during the second quarter. BlackRock Inc. now owns 427,534,404 shares of the biopharmaceutical company’s stock worth $13,980,372,000 after buying an additional 3,464,207 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in Pfizer by 8,940.8% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 3,426,457 shares of the biopharmaceutical company’s stock valued at $112,045,000 after buying an additional 3,388,557 shares during the period. Finally, First Trust Advisors LP lifted its holdings in Pfizer by 64.2% in the second quarter. First Trust Advisors LP now owns 7,606,699 shares of the biopharmaceutical company’s stock valued at $248,739,000 after buying an additional 2,973,005 shares during the period. 69.08% of the stock is currently owned by institutional investors.
Shares of NYSE PFE traded down $1.07 during midday trading on Tuesday, reaching $36.26. The company’s stock had a trading volume of 681,066 shares, compared to its average volume of 29,878,367. Pfizer Inc. has a 12-month low of $27.88 and a 12-month high of $41.99. The firm has a 50 day moving average price of $37.01 and a 200-day moving average price of $36.63. The stock has a market capitalization of $207.49 billion, a P/E ratio of 14.81, a PEG ratio of 3.10 and a beta of 0.66. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.42 and a quick ratio of 1.16.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 27th. The biopharmaceutical company reported $0.72 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.01. Pfizer had a return on equity of 25.11% and a net margin of 28.80%. The firm had revenue of $12.13 billion for the quarter, compared to the consensus estimate of $12.30 billion. During the same quarter in the previous year, the business earned $0.75 EPS. The company’s revenue was down 4.3% compared to the same quarter last year. On average, equities analysts predict that Pfizer Inc. will post 2.84 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, November 6th will be paid a $0.38 dividend. The ex-dividend date of this dividend is Thursday, November 5th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 4.19%. Pfizer’s payout ratio is presently 51.53%.
Several equities analysts recently issued reports on PFE shares. Sanford C. Bernstein started coverage on shares of Pfizer in a report on Tuesday, November 10th. They issued a “market perform” rating and a $42.00 target price on the stock. JPMorgan Chase & Co. set a $36.00 target price on shares of Pfizer and gave the company a “neutral” rating in a report on Monday, November 9th. Morgan Stanley upped their price objective on shares of Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. ValuEngine lowered shares of Pfizer from a “hold” rating to a “sell” rating in a report on Thursday, July 30th. Finally, Truist began coverage on shares of Pfizer in a report on Friday, October 23rd. They set a “buy” rating and a $42.00 price objective on the stock. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have given a buy rating to the stock. Pfizer currently has a consensus rating of “Hold” and a consensus target price of $39.79.
In other Pfizer news, major shareholder Pfizer Inc bought 1,200,000 shares of the business’s stock in a transaction dated Tuesday, October 27th. The shares were purchased at an average price of $10.00 per share, for a total transaction of $12,000,000.00. Following the purchase, the insider now directly owns 27,349,211 shares of the company’s stock, valued at $273,492,110. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 0.08% of the stock is owned by insiders.
Pfizer Inc develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands.
Featured Story: Day Trading
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.